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Background: In 2009, treatment guidelines were updated to recommend KRAS testing at diagnosis for patients
with metastatic colorectal cancer (mCRC). We investigated KRAS testing rates over time and compared
characteristics of KRAS-tested and not-tested patients in a community-based oncology setting.
Methods: Adult patients with a diagnosis of mCRC from 2008–2011 were selected from the ACORN Data Warehouse
(ACORN Research LLC, Memphis, TN). Text mining of physician progress notes and full chart reviews identified KRAS-
tested patients, test dates, and test results (KRAS status). The overall proportion of eligible patients KRAS-tested in each
calendar year was calculated. Among KRAS-tested patients, the proportion tested at diagnosis (within 60 days) was
calculated by year. Univariate and multivariate analyses were used to compare patient characteristics at diagnosis
between tested and not-tested cohorts, and to identify factors associated with KRAS testing.
Results: Among 1,363 mCRC patients seen from 2008–2011, 648 (47.5%) were KRAS-tested. Among newly diagnosed
mCRC patients, the rate of KRAS testing increased from 5.9% prior to 2008, to 13.9% in 2008, and then jumped
dramatically to 32.3% in 2009, after which a modest yearly increase continued. The proportions of KRAS-tested patients
who had been diagnosed in previous years but not tested previously increased from 17.7% in 2008 to 27.0% in 2009,
then decreased to 19.0% in 2010 and 17.6% in 2011. Among patients who were KRAS-tested, the proportions tested at
the time of diagnosis increased annually (to 78.4% in 2011). Patients more likely to have been tested included those
with lung metastases, poor performance status, more comorbidities, and mCRC diagnosis in 2009 or later.
Conclusions: The frequency of KRAS testing increased over time, corresponding to changes in treatment guidelines
and epidermal growth factor receptor inhibitor product labels; however, approximately 50% of eligible patients were
untested during the study period.
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Colorectal cancer (CRC) is the third leading cause of can-
cer deaths in the United States (US), with an estimated
142,820 new cases to be diagnosed in 2013 [1]. At the time
of diagnosis, approximately 39% of patients with CRC
present with localized disease (stages I-II), 37% present
with regional metastases (stage III), and 19% with distant
metastases (stage IV, or metastatic CRC [mCRC]) [2]. In
mCRC, common sites for metastases include the liver,* Correspondence: cuyun_carter_gebra@lilly.com
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unless otherwise stated.peritoneum, and lung. The 5-year survival rate for patients
diagnosed with mCRC is approximately 10% to 12% [1,3].
Conventional chemotherapies used to treat mCRC
include combinations of 5-fluorouracil, leucovorin, cape-
citabine, oxaliplatin, and irinotecan [4]. Bevacizumab
(Avastin) is also indicated for treatment of mCRC in
combination with conventional chemotherapies [5]. In
addition, targeted therapies that interfere with epidermal
growth factor receptor (EGFR)-mediated pathways (i.e.,
EGFR inhibitors) have been developed for the treatment of
mCRC. In 2004, the EGFR inhibitor cetuximab (Erbitux)
was approved in the US for the second-line treatment ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Carter et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:29 Page 2 of 8mCRC in patients whose tumors overexpress EGFR [6],
and in 2006, the EGFR inhibitor panitumumab (Vectibix)
was approved for the second-line treatment of mCRC in
patients with disease progression on or following conven-
tional chemotherapies [7]. Since then, cetuximab has had
its indication revised to include first- and second-line
treatment of mCRC, in combination with conventional
chemotherapies or as a single agent in patients who have
failed oxaliplatin- and irinotecan-based therapy [6]. Simi-
larly, in 2014, panitumumab had its indication revised to
include first-line treatment of mCRC, in combination with
conventional chemotherapies or as a single agent in pa-
tients who have failed fluoropyrimidine therapy [7].
KRAS is an oncogene involved with the EGFR signal-
ing pathway; KRAS activity in mCRC is associated with
increased cell proliferation, angiogenesis, migration, and
survival of the cancer tissue [4,8]. In mCRC, only tumors
carrying the normal (or wild-type [WT]) allele of the
KRAS oncogene (i.e., KRAS mutation-negative) may have
favorable responses to these EGFR inhibitors, and pa-
tients whose tumors carry certain KRAS mutations do
not derive any benefit [8-10]. Approximately 60% of pa-
tients with mCRC carry the WT KRAS allele, and thus
these patients may be appropriate candidates for therapy
with EGFR inhibitors [4,8,9]. A recent study has sug-
gested that KRAS mutation status is also predictive of
long-term prognosis among patients with mCRC treated
by conventional chemotherapy [11].
In light of these findings, the National Comprehensive
Cancer Network (NCCN) updated its treatment guide-
lines for mCRC in late 2008, recommending that KRAS
testing on tumors and metastases be part of the pretreat-
ment workup for all patients with metastatic (stage IV)
disease [4,12,13]. In mid-2009, NCCN updated these
guidelines, stipulating that only patients with WT KRAS
genotypes should receive treatment with EGFR inhibi-
tors [13-15]. Similarly, the American Society for Clinical
Oncology (ASCO) recommended that all patients with
mCRC who are candidates for anti-EGFR antibody ther-
apy have their tumors tested for KRAS mutations, and
that those in whom mutations in codon 12 or 13 are
detected should not receive EGFR inhibitors [15,16]. In
2009, the US Food and Drug Administration (FDA) re-
quired that the labels for both cetuximab and panitumu-
mab be updated to restrict these agents to patients with
mCRC whose tumors carry the WT KRAS genotype
[6,7,17]. Most recently, in 2012, the FDA approved the
first companion diagnostic test for KRAS genotyping
(the therascreen® RGQ PCR Kit).
The objectives of the present study were to investigate
KRAS testing rates over time and to compare the char-
acteristics of tested and not-tested patients in a sample
of community-based US oncology practices. In recent
years, the clinical uptake and utilization of KRAS testingin mCRC, and the impact of KRAS testing on treatment
outcomes, have been investigated in observational studies
performed in Europe, Latin America, Asia [18], and the
US [19]. In contrast to previous US studies, the current
analysis includes patients covered by multiple healthcare
payers (e.g., commercial, Medicare, Medicaid) enrolled in
various plan types as well as self-pay patients.
Methods
Data source
The primary data source for this study was the ACORN
EMR Warehouse (ACORN Research LLC, Memphis, TN),
a database which contains information on approximately
175,000 patients seen in 12 community-based oncology
practices by 120 oncologists across the US since 2004.
This database links electronic medical records (EMRs),
which contain patient demographics, tumor type and
stage, treatments, and outcomes, with laboratory results
and other clinical information. One limitation is that the
results of KRAS testing are not captured in standard EMR
data fields; however, this information is often found in
physician progress notes, which ACORN stores electron-
ically in the data warehouse to complement the EMR data.
Deidentified data on patients meeting select criteria were
provided by ACORN for analysis.
Study population
Adult patients (aged 18 years or older) with a primary
diagnosis of mCRC (based on ICD-9-CM codes [CRC:
ICD-9-CM 153.x-154.1; metastatic disease: ICD-9-CM
197.x-198.x] and/or listing of “stage IV” or “stage 4” in
physician notes) between January 1, 2008 and December
31, 2011 were identified. Patients with evidence of other
primary cancers and those with only one visit to a con-
tributing practice were excluded. All database records
for included patients were extracted through March 31,
2012. For the purposes of the present study, “baseline”
was defined as the time of first diagnosis of metastatic
disease.
Development and validity of KRAS testing algorithms
Algorithms for electronic text mining of physician pro-
gress notes were developed by ACORN to identify
whether patients with mCRC were tested for KRAS and
whether a patient’s tumor designation was WT or mu-
tant [20]. These text mining algorithms were validated
by trained oncology nurse abstractors who reviewed a
random selection of 300 charts. When applied to the
dataset, the best-performing algorithm (employing a
random forest approach) achieved a kappa value (i.e.,
how often the model agreed with the chart review,
accounting for chance) of 0.97, with a positive predictive
value of 96.4% and a negative predictive value of 98.0%
[20]. Trained oncology nurses then reviewed the medical
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tested” and recorded the results (WT, mutant, or un-
known [ie, no evidence of testing results]) and the date of
testing. The data were then merged with the study popula-
tion data using blinded patient identifiers.
Proportion of population tested
The overall rate of KRAS testing was based on the num-
ber of patients tested at any point between diagnosis of
CRC and end of follow-up, divided by the total study
sample. Rate of KRAS testing by year was based on the
number of patients tested in the given year divided by
the number of patients eligible for the given year. Pa-
tients eligible for testing, by year, was the sum of pa-
tients newly diagnosed with mCRC within a given year
and those diagnosed with mCRC in previous years (with
a visit to a participating provider within the given year)
but not previously KRAS-tested. Finally, the proportion
of those tested at diagnosis was defined as those tested
within 60 days (before or after) of their first recorded
mCRC diagnosis date within a given year divided by the
total number of study patients diagnosed with mCRC in
that same year.
Statistical analyses
Demographic information, disease characteristics, and
clinical history at first diagnosis of metastatic disease
were compared between KRAS-tested and not-tested pa-
tients using chi-squared and Student’s t-tests. A logistic
regression model was used to identify baseline factors
associated with ever being KRAS-tested and with being
tested at diagnosis. The level of statistical significance
for all tests was 0.05 and results were not adjusted for
multiple comparisons. All statistical analyses were per-
formed using SAS version 9.2, on a PC platform.
Results
Among 12,420 patients with a CRC diagnosis between
2008 and 2011, 2,080 were 18 years of age or older with
documented distant metastases. Of these patients, 686
were excluded because they had evidence of other can-
cers, and an additional 31 were excluded because they
only had one visit to the contributing practice, yielding a
study population of 1,363 patients (Table 1). Of these
1,363 patients, 648 (47.5%) were KRAS-tested at some
point in their disease. Of these 648 tested patients, 312
patients (48.1%) were identified as WT, 274 patients
(42.3%) as mutant, and 62 patients (9.6%) as unknown
(no evidence of testing results). Proportions of those
patients KRAS-tested were similar between males and
females, but KRAS testing was more frequent among
patients aged 65 years and older than among younger
patients (p = 0.002). Patients tested for KRAS were also
less likely to be self-pay (3.9% vs. 8.1% for not-testedpatients, p = 0.040), were more likely to be enrolled in a
clinical trial (13.7% vs. 8.7%, p = 0.003), had more co-
morbid conditions (mean, 3.7 vs. 2.7, p < 0.001), and had
poorer performance status (ECOG 2–4: 41.9% vs. 34.0%,
p = 0.042) at diagnosis. No significant differences were
found between tested and nontested cohorts for race,
gender, cancer location (colon, rectum, or both), tumor
histologic grade, or whether patients were newly diag-
nosed versus having recurrent mCRC.
The proportions of eligible patients ever KRAS-tested
increased from 5.9% to 16.1% in the calendar year 2008
(prior to the inclusion of testing recommendations in
the NCCN guidelines) and continued to increase to
29.1% in 2009 (coincident with NCCN and ASCO guid-
ance updates and US labeling changes regarding KRAS
genotype for cetuximab and panitumumab), after which
the proportions of tested patients remained fairly con-
sistent. However, as shown in Figure 1A, when looking
separately at the two populations of eligible patients, the
proportions of newly diagnosed mCRC patients KRAS-
tested increased from 13.9% in 2008 to 40.5% in 2011,
while patients who were previously diagnosed, but not
tested, tended to remain not tested over time. Among
patients who were KRAS-tested, the proportions of those
tested at the time of diagnosis increased greatly over the
four years testing was widely available (27.4% in 2008 to
78.4% in 2011) (Figure 1B).
Baseline characteristics believed to be associated with
ever being KRAS-tested, and with being KRAS-tested at
diagnosis (among those tested), were modeled in a mul-
tivariable model (Figure 2A and B, respectively). Among
eligible patients, those more likely to have been KRAS-
tested (Figure 2A) included those with lung metastases
(OR: 1.58, 95% CI: 1.11 to 2.26; ref: those with no lung
metastases), those with poor performance status (OR:
1.45, 95% CI: 1.04 to 2.03; ref: those with good perform-
ance status), those with more comorbid conditions (OR:
1.10, 95% CI: 1.06 to 1.14), those diagnosed during the
first three quarters of 2009 (OR: 1.46, 95% CI: 1.04 to
2.03; ref: those diagnosed in 2008 or earlier), and those
diagnosed in the fourth quarter of 2009 or later (OR:
1.65, 95% CI: 1.12 to 2.43; ref: those diagnosed prior to
the fourth quarter of 2009). Those less likely to have
been tested included self-pay patients (OR: 0.35, 95% CI:
0.17 to 0.72; ref: those with Medicaid), and those with
peritoneal metastases (OR: 0.37, 95% CI: 0.17 to 0.78;
ref: those without peritoneal metastases), ovarian metas-
tases (OR: 0.32, 95% CI: 0.11 to 0.98; ref: those without
ovarian metastases), or other metastases (OR: 0.47, 95%
CI: 0.25 to 0.87; ref: those without other metastases).
Among patients who were KRAS-tested, the only fac-
tor significantly associated with being tested at diagnosis
(Figure 2B) was the calendar time when testing was con-
ducted. Testing at diagnosis was 2.1 times more likely to
Table 1 Demographic characteristics of the eligible study
population












African American 182 (13.4%)
Hispanic 8 (0.6%)
Other 23 (1.7%)







Death reported 653 (47.9%)






Newly diagnosed 482 (35.4%)
Recurrent 43 (3.2%)
Other 4 (0.3%)
Not reported 834 (61.2%)
Consolidated/Combined ECOG/KPS score
ECOG = 0 to 1/KPS = 80 to 100 466 (34.2%)
ECOG = 2-4/KPS = 10-70 274 (20.1%)
Not reported 623 (45.7%)
Histologic grade
Well differentiated 40 (2.9%)
Moderately differentiated 265 (19.4%)
High grade/poorly differentiated 89 (6.5%)
Undifferentiated 3 (0.2%)
Cannot be assessed 30 (2.2%)
Not reported 936 (68.7%)






Not tested 715 (52.5%)
Abbreviations: ECOG Eastern Cooperative Oncology Group, KPS Karnofsky
performance score, mCRC metastatic colorectal cancer.
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CI: 1.24 to 3.52; ref: those diagnosed in 2008 or earlier)
and 6.2 times more likely to occur from the fourth quar-
ter of 2009 onward (OR: 6.15, 95% CI: 2.95 to 12.81; ref:
those diagnosed prior to the fourth quarter of 2009)
compared to the period before 2009.
Discussion
Using text-based documents (e.g., physician progress
notes) electronically stored within the ACORN Data
Warehouse, a text-mining algorithm and a correspond-
ing statistical model was developed to accurately identify
patients with mCRC who were and were not tested for
KRAS genotype. This study is the first to investigate the
uptake of KRAS testing using EMR data from community-
based oncology practices across the US representing all
insurance types and multiple health plan types. A standard
field to capture whether a patient was KRAS-tested and
the results of testing is not available in EMR data. In the
present study, this was addressed by text mining physician
notes and subsequent chart review of those patients iden-
tified as KRAS-tested. As advances in biomarker identifi-
cation and testing in cancers of all types continue,
oncology-based EMR systems will need to accommodate
the capture of this information.
Corresponding to changes in treatment guidelines and
US product labels for anti-EGFR agents, KRAS testing
increased annually between 2008 and 2009 and remained
constant through 2011. Nevertheless, despite the increas-
ing frequency of testing appropriate patients for KRAS
genotype, slightly more than half the patients (52.5%)
show no evidence in their medical records of having been
KRAS-tested. These patients may include those whom
physicians consider inappropriate candidates for anti-
EGFR therapies, those diagnosed prior to the adoption of
KRAS testing guidelines, and those with tumors progres-
sing too quickly for KRAS genotype-directed treatment
decisions. Given that data supporting first-line use of an
EGFR inhibitor (cetuximab) over first-line bevacizumab
[21] have emerged more recently, most physicians were
likely using EGFR inhibitors between 2008 and 2011 in
later lines of therapy, and thus, may have waited to test for
AB
Figure 1 KRAS testing by calendar year. Proportion of newly diagnosed patients with mCRC tested for KRAS genotype and proportion of
patients diagnosed in a prior year but not previously tested for KRAS genotype by calendar year (A), and among KRAS-tested patients, proportion
tested at time of mCRC diagnosis by calendar year (B). Abbreviation: mCRC =metastatic colorectal cancer.
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As such, it is possible that patients diagnosed between
2008 and 2011 had not progressed to the point of con-
sidering EGFR inhibitor treatment (and accordingly KRAS-
tested) during the follow-up period included in the
dataset. If this is true, then our findings may support a
practice of KRAS testing at the time of potential EGFR
inhibitor use rather than physicians’ lack of knowledge
about or uptake of KRAS testing in their practice. Indeed,
only a fraction (approximately 50%) of patients with
mCRC who receive first-line therapy go on to receive
second-line therapy and beyond [22,23]. Additionally, the
study period for this analysis (2008–2011) occurred before
the availability of an FDA-approved KRAS diagnostic test
in 2012; the availability of such tests may affect the
proportion of patients who are KRAS-tested in the future.This analysis suggests that certain patient characteris-
tics may influence whether or not a patient is KRAS-
tested, but that once a clinician decides to test for KRAS,
patient characteristics play less of a role in influencing
the timing of the decision. In this study population, a
substantial proportion of patients were aged 75 years
and older; as age increases, patients may be less likely to
ever have been KRAS-tested. In the model, when the age
variable was changed from a quasi-continuous variable
to a discrete binary variable (i.e., patients aged 75 and
older), the model results were not dramatically different
(data not shown).
Although the proportion of tested patients identified as
KRAS-WT (48%) was slightly lower than previously re-
ported (57%) [18], the 10% of patients with KRAS-status
unknown (i.e., no evidence of testing) is consistent with
AB
Figure 2 Baseline characteristics associated with KRAS testing. From multivariate logistic regression modeling among all eligible patients
(A) and among KRAS-tested patients, those tested at time of mCRC diagnosis (B). Reference groups: gender-male, race-Caucasian, insurance-Medicaid,
location of lesions-both, histology grade-high/moderately differentiated, ECOG/KPS score-(0-1/80-100), mCRC diagnosis-2008 or earlier. Abbreviations:
ECOG = Eastern Cooperative Oncology Group; KPS = Karnofsky performance score; mCRC =metastatic colorectal cancer; Q = quarter.
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likely the result of the pathologist having too little sample
to conduct KRAS testing rather than the result being
unavailable in the chart.
Access to reimbursement (for the costs of both KRAS
testing and of anti-EGFR therapies) may be a factor
affecting KRAS testing for appropriate patients, particu-
larly prior to the adoption of the updated treatment
guidelines. Additionally, it appears that healthier patients
are less likely to be tested than less healthy patients (i.e.,
those with poor performance status or more comorbidities).One consideration is that patients with poorer perform-
ance status and more comorbidities may be better candi-
dates for single-agent EGFR inhibitor therapy than other
combination regimens, necessitating KRAS testing to
determine course of treatment.
Among KRAS-tested patients, testing at the time of
mCRC diagnosis increased annually from 27.4% in 2008
to 78.4% in 2011, corresponding to current recommenda-
tions that patients be KRAS-tested at diagnosis of meta-
static disease to aid in informing their overall treatment
plan. It appears that the community-based oncologists
Carter et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:29 Page 7 of 8serving this patient population were not only aware of the
changes in clinical guidelines (and corresponding changes
to EGFR inhibitor product labels), but quickly began
implementing KRAS testing as part of the workup for
most newly diagnosed patients with mCRC.
A limitation of this study is the fact that the contribut-
ing oncology practices used one of three EMR systems
that feed the Acorn Data Warehouse; this may add vari-
ability to which data elements are captured in addition
as to how they are captured. An additional data limita-
tion is missing data on care provided outside of the
ACORN-contributing practices. The results presented
may not be generalizable to community-based oncology
practices at large.
Conclusions
In conclusion, it appears that although there has been an
increase in awareness of the need for KRAS testing
among patients with mCRC (i.e., an increase in the
proportion of eligible patients tested; and among those
tested, an increase in the proportion of those tested at
first diagnosis of metastatic disease), the overall propor-
tion of patients KRAS-tested (approximately 50%) could
be increased further to improve therapy planning for pa-
tients and ultimately improve patient outcomes. Testing
rates have likely improved since the period examined
within this study (2008–2011) due to further label
changes and availability of an FDA-approved test, thus
increasing awareness and improving access to testing.
Continued education and awareness to promote the
importance of KRAS testing is warranted, especially as
new biomarkers emerge in the treatment of mCRC. As
the continuum of care for mCRC evolves and the opti-
mal sequence of available agents is better characterized,
maximizing knowledge about predictive and prognostic
biomarkers at the time of diagnosis will help clinicians
develop short- and long-term individualized therapeutic
strategies for their patients.
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